Immune Targeting Systems (ITS) Ltd.

Immune Targeting Systems (ITS) is a London based biotech company developing vaccines for mutating viruses underpinned by its DepoVaccine and High Density Antigen identification technology platforms. ITS’s lead program is a synthetic universal influenza vaccine targeting all potential seasonal and pandemic flu strains. A clinical trial application was submitted to the UK MHRA in July 2010 and clinical testing is expected to start in Q3-2010. Lead-optimisation has commenced on a universal Hepatitis-B therapeutic vaccine (genotypes A,B,C,D & Other).

DepoVaccines deliver high density antigens to the immune system and promote a vaccine depot at the injection site. This depot promotes potent, durable and recallable antiviral T-cell immunity without adjuvants. Vaccine design and antigen selection specifically address key aspects of human immunological-vaccine performance required for clinical success; (i) vaccine responder frequency >95%, (ii) breadth of response, (iii) magnitude of response, & (iv) multi-re-use capability afforded by synthetic long-peptides.

HD-Antigens are naturally occurring viral peptides (35 amino acids) which are highly conserved across all viral strains and contain high density clusters of CD4 T-Helper and CD8 Cytotoxic T-Lymphocyte epitopes ensuring broad human population coverage. HD-Antigens are conjugated to a fluorocarbon vector. Each vaccine contains multiple (6-8) HD-antigens as a freeze dried thermostable nanoparticle based formulation. Candidates for Hepatitis-B & C, HIV, EBV tumours await development funding or partners. If you are interested in discussing partnering or investment opportunities please contact Carlton Brown: carlton.brown@its-innovation.com